Price$152.56+1.85 (+1.23%)
01:30 PM07:45 PM
News · 26 weeks129+183%
2026-03-012026-08-23
Mix5990d
- Other24(41%)
- Insider22(37%)
- SEC Filings6(10%)
- Analyst3(5%)
- Dividends2(3%)
- Earnings2(3%)
Latest news
25 items- ANALYSTMerck downgraded by RBC Capital Mkts with a new price targetRBC Capital Mkts downgraded Merck from Outperform to Sector Perform and set a new price target of $150.00
- ANALYSTMerck upgraded by Morgan Stanley with a new price targetMorgan Stanley upgraded Merck from Equal-Weight to Overweight and set a new price target of $179.00
- PRMerck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV MelanomaFirst and only combination regimen to demonstrate statistically significant and clinically meaningful improvements in RFS and DMFS compared to KEYTRUDA alone for these patients in the adjuvant melanoma setting The Companies plan to present data at an upcoming international medical meeting and will engage with regulators on filing submissions for intismeran autogene in combination with KEYTRUDA Intismeran autogene is an mRNA-based individualized neoantigen therapy (INT) designed specifically for each patient based on the unique set of mutations within their tumor to train and activate the immune system to recognize and fight cancer Merck (NYSE:MRK), known as MSD outside of the United S
- INSIDEREVP, Access, Policy & Comms Guindo Chirfi sold $1,350,000 worth of shares (10,000 units at $135.00), decreasing direct ownership by 21% to 36,613 units (SEC Form 4)4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDEREVP, General Counsel Zachary Jennifer exercised 54,927 shares at a strike of $109.78 and sold $10,718,495 worth of shares (80,315 units at $133.46), decreasing direct ownership by 36% to 45,509 units (SEC Form 4)4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDEREVP&Pres, Merck Animal Heallth Deluca Richard R. sold $5,942,369 worth of shares (45,320 units at $131.12), decreasing direct ownership by 29% to 110,167 units (SEC Form 4)4 - Merck & Co., Inc. (0000310158) (Issuer)
- ANALYSTMerck upgraded by Daiwa Securities with a new price targetDaiwa Securities upgraded Merck from Neutral to Outperform and set a new price target of $143.00
- INSIDEREVP&Pres, Merck Animal Heallth Deluca Richard R. sold $788,773 worth of shares (6,050 units at $130.38), decreasing direct ownership by 4% to 155,487 units (SEC Form 4)4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDEREVP & Pres. MMD Maraldo David R. exercised 18,706 shares at a strike of $82.25 and sold $2,407,797 worth of shares (18,706 units at $128.72) (SEC Form 4)4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDEREVP,Chief Info&Digital Officer Williams David Michael exercised 52,847 shares at a strike of $74.49 and sold $6,805,145 worth of shares (52,847 units at $128.77), increasing direct ownership by 0.00% to 31,716 units (SEC Form 4)4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDEREVP, Access, Policy & Comms Guindo Chirfi sold $1,965,000 worth of shares (15,000 units at $131.00), decreasing direct ownership by 24% to 46,613 units (SEC Form 4)4 - Merck & Co., Inc. (0000310158) (Issuer)
- SECSEC Form 10-Q filed by Merck & Company Inc.10-Q - Merck & Co., Inc. (0000310158) (Filer)
- SECSEC Form 13F-HR filed by Merck & Company Inc.13F-HR - Merck & Co., Inc. (0000310158) (Filer)
- PRU.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second SeasonEMA also accepts application for the same population for ENFLONSIA based on results from the Phase 3 SMART trial If approved, children under two years of age at increased risk for severe RSV disease will be eligible to receive an additional dose of ENFLONSIA for their second RSV season Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for ENFLONSIA™ (clesrovimab-cfor) to expand its indication to include prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in children under two years of age at increased r
- PRHealth Canada Approves KEYTRUDA® for the treatment of adult patients with muscle invasive bladder cancer who are ineligible for cisplatin containing chemotherapy, in combination with enfortumab vedotin, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatmentKIRKLAND, QC, Aug. 4, 2026 /CNW/ -- Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced that KEYTRUDA® (pembrolizumab for injection), Merck's anti-PD-1 therapy, in combination with enfortumab vedotin, an antibody-drug conjugate (ADC), is approved by Health Canada as neoadjuvant treatment and then continued after radical cystectomy (RC) as adjuvant treatment, for adults with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-containing chemotherapy. This approval is based on results from the pivotal Phase 3 KEYNOTE-905 trial (also known as EV-303), which was conducted in collabor
- SECMerck & Company Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Merck & Co., Inc. (0000310158) (Filer)
- PRMerck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse PipelineSales Growth Reflects Continued Strength in Oncology, Including Initial Uptake of KEYTRUDA QLEX, and Animal Health, Plus Contributions From Launches Such as WINREVAIR Financial Highlights Total Worldwide Sales Were $16.6 Billion (5% Growth; 4% Growth ex-FX) KEYTRUDA/KEYTRUDA QLEX1 Sales Were $8.4 Billion (5% Growth; 4% Growth ex-FX); Includes KEYTRUDA QLEX Sales of $463 Million WINREVAIR Sales Were $588 Million (75% Growth; 75% Growth ex-FX) Animal Health Sales Were $1.8 Billion (8% Growth; 5% Growth ex-FX) GAAP Loss per Share Was $0.54; Non-GAAP Loss per Share Was $0.13; GAAP and Non-GAAP Loss per Share Include a Charge of $2.31 per Share for the Acquisition of Terns
- PRMerck Announces Fourth-Quarter 2026 DividendMerck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company’s common stock for the fourth quarter of 2026. Payment will be made on October 7, 2026, to shareholders of record at the close of business on September 15, 2026. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier resear
- PRMerck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 DevelopmentMulti-faceted strategy aims to enable rapid, broad and sustainable access to alimatravir (MK-8527), if approved, in low- and middle-income countries Voluntary licensing agreements cover 129 countries in regions which account for the substantial majority of new HIV diagnoses globally As Phase 3 trials continue, Merck is committed to advancing access plans, working in close collaboration with the HIV community and global health stakeholders Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced early components of a multi-faceted strategy to provide rapid, broad and sustainable access in low- and middle-income countries (LMICs) to alimatravir (MK-8527),
- PRTessera Therapeutics Appoints Joseph Romanelli as President and Chief Executive OfficerVeteran pharmaceutical executive to lead Tessera's next phase of growth as the company advances Gene Writing from platform innovation toward a broad clinical pipeline of genetic medicinesSOMERVILLE, Mass., July 23, 2026 /PRNewswire/ -- Tessera Therapeutics ("Tessera"), the biotechnology company pioneering a new approach to genetic medicine known as Gene Writing™, today announced the appointment of Joseph Romanelli as President and Chief Executive Officer. Romanelli succeeds Michael Severino who has led the company since June 2022. Romanelli will join Tessera's board of directors and also join Tessera's founder, Flagship Pioneering, as a CEO-Partner.
- PRMerck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with HypercholesterolemiaAt week 24 in the CORALreef Lipids and CORALreef HeFH trials, LIPFENDRA significantly reduced LDL-C by a placebo-adjusted 56% and 59%, respectively LIPFENDRA is a novel macrocyclic peptide that binds to PCSK9 and inhibits the interaction of PCSK9 with LDL receptors Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved LIPFENDRA® (enlicitide) tablets 20 mg as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). LIPFENDRA is a novel macrocyclic peptide and is the first F
- PRMerck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026Late-breaker presentations will highlight investigational, once-weekly oral combinations of islatravir with lenacapavir (Phase 3 ISL/LEN) and with ulonivirine (Phase 2b ISL+ULO) in adults with virologically-suppressed HIV-1 Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that new data from its research pipeline for HIV treatment and prevention will be presented at the 26th International AIDS Conference (AIDS 2026), taking place July 26-31, 2026, in Rio de Janeiro, Brazil. "Building on the momentum of the recent FDA approval of IDVYNSO, AIDS 2026 is an exciting moment to showcase the next chapter of Merck’s HIV pipeline – particularly our focus on
- PRKEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to ChemotherapyKEYTRUDA is the first and only PD-1 inhibitor to improve PFS compared to platinum doublet chemotherapy for these patients in a Phase 3 trial Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the Phase 3 KEYNOTE‑C93 trial evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, met its primary endpoint of progression-free survival (PFS) for the treatment of patients with mismatch repair deficient (dMMR) advanced or recurrent endometrial cancer who had not previously received systemic chemotherapy or who experienced recurrence more than six months after completing prior adjuvant therapy. KEYTRUDA is the first and only PD-1 inhibitor to show a st
- INSIDERSEC Form 4 filed by Director Seidman Christine E4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDERSEC Form 4 filed by Director Karsanbhai Surendralal Lanca4 - Merck & Co., Inc. (0000310158) (Issuer)
MRK FAQ
7 questionsWhat does Merck & Company Inc. do?
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected...Where does MRK stock trade?
Merck & Company Inc. (MRK) is listed on NYSE.What sector and industry is MRK in?
Merck & Company Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.Does MRK pay a dividend?
Yes. MRK's next ex-dividend date is 2026-09-15 with a declared cash dividend of $0.85 per share, payable 2026-10-07.What are analysts saying about MRK?
Merck & Company Inc. has had 8 recent analyst actions on file. The most recent action was from RBC Capital Mkts: Sector Perform on 2026-08-20.What companies are similar to MRK?
Notable peers in the same industry include NVS (Novartis AG), AZN (AstraZeneca PLC), AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), PFE (Pfizer Inc.). Compare MRK side-by-side with any of them on Quantisnow.How can I track MRK on Quantisnow?
Quantisnow aggregates Merck & Company Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MRK to receive live email and push alerts on every new disclosure.